Ocumension Therapeutics Valuation

Is 5DG undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 5DG when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 5DG (€0.74) is trading below our estimate of fair value (€1.82)

Significantly Below Fair Value: 5DG is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 5DG?

Other financial metrics that can be useful for relative valuation.

5DG key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue10.6x
Enterprise Value/EBITDA-11.5x
PEG Ration/a

Price to Sales Ratio vs Peers

How does 5DG's PS Ratio compare to its peers?

The above table shows the PS ratio for 5DG vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.6x
PSG PharmaSGP Holding
2.5x7.0%€278.2m
93M1 MPH Health Care
2.9x6.0%€101.0m
DMP Dermapharm Holding
1.6x3.8%€1.8b
2FJ0 Pierrel
3.4xn/a€92.8m
5DG Ocumension Therapeutics
13.6x39.6%€4.6b

Price-To-Sales vs Peers: 5DG is expensive based on its Price-To-Sales Ratio (13.6x) compared to the peer average (2.6x).


Price to Earnings Ratio vs Industry

How does 5DG's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a19.6%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a19.6%
n/an/an/a
No more companies

Price-To-Sales vs Industry: 5DG is expensive based on its Price-To-Sales Ratio (13.6x) compared to the European Pharmaceuticals industry average (4.6x).


Price to Sales Ratio vs Fair Ratio

What is 5DG's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

5DG PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio13.6x
Fair PS Ratio6x

Price-To-Sales vs Fair Ratio: 5DG is expensive based on its Price-To-Sales Ratio (13.6x) compared to the estimated Fair Price-To-Sales Ratio (6x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 5DG forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€0.73
€1.14
+55.7%
13.2%€1.36€1.02n/a3
Sep ’25€0.63
€1.15
+84.0%
12.9%€1.36€1.04n/a3
Aug ’25€0.79
€1.10
+38.8%
23.7%€1.44€0.82n/a3
Jul ’25€0.79
€1.11
+41.0%
23.3%€1.46€0.83n/a3
Jun ’25€0.78
€1.11
+43.7%
23.3%€1.46€0.83n/a3
May ’25€0.83
€1.00
+19.4%
32.7%€1.45€0.71n/a3
Apr ’25€0.66
€1.00
+51.0%
32.7%€1.45€0.71n/a3
Mar ’25€0.58
€1.37
+137.0%
18.7%€1.74€1.04n/a4
Feb ’25€0.56
€1.37
+145.4%
18.7%€1.74€1.04n/a4
Jan ’25€0.75
€1.48
+97.8%
18.9%€1.80€1.16n/a4
Dec ’24€0.79
€1.53
+95.4%
16.5%€1.84€1.26n/a4
Nov ’24€0.90
€1.53
+71.4%
16.5%€1.84€1.26n/a4
Oct ’24€0.90
€1.53
+70.4%
16.5%€1.84€1.26€0.704
Sep ’24€0.95
€1.54
+62.5%
15.0%€1.83€1.30€0.634
Aug ’24€1.09
€1.63
+49.8%
15.8%€2.04€1.33€0.794
Jul ’24€0.86
€1.72
+99.6%
9.1%€1.95€1.53€0.794
Jun ’24€0.80
€1.77
+123.0%
9.2%€2.04€1.59€0.784
May ’24€0.98
€1.77
+80.0%
9.2%€2.04€1.59€0.834
Apr ’24€1.13
€1.87
+65.3%
6.9%€2.06€1.73€0.664
Mar ’24€1.14
€1.91
+67.7%
7.4%€2.13€1.77€0.584
Feb ’24€1.42
€2.00
+41.0%
9.0%€2.18€1.74€0.564
Jan ’24€1.12
€2.01
+79.5%
8.8%€2.17€1.74€0.754
Dec ’23€0.94
€1.99
+111.7%
8.3%€2.15€1.73€0.794
Nov ’23€0.95
€2.05
+115.8%
8.3%€2.22€1.78€0.904
Oct ’23€1.25
€1.99
+59.4%
14.6%€2.29€1.50€0.905

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies